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Abstract. The aim of the present study was to investigate 
the utility of 3D cell culture and in vitro cytotoxicity assays, 
performed using cells derived from biopsies obtained prior to 
the initiation of preoperative chemoradiotherapy (preop-CRT), 
in predicting tumor response to chemoradiotherapy following 
preop-CRT in rectal cancer. Biopsies were obtained from 
49 patients with locally advanced rectal cancer that underwent 
preop-CRT between August 2015 and March 2017. Tumor 
tissue was obtained before initiating preop-CRT. The response 
to chemoradiation was assessed by in vitro cytotoxicity assay 
following 3D cell culture and radiation treatment. The associa-
tions between the results from the cytotoxicity assay, and tumor 
regression grade (TRG) and yp node (ypN) positivity were 
investigated. Among 49 patients, 26 patients were available 
for analysis. Cytotoxicity ranged from 25.5-72.6% (median, 
47.6%). There was no difference in cytotoxicity according 
to the TRGs 1-5 (P=0.940), or good tumor response (TRGs 
1‑2 vs. TRGs 3‑5; P=0.729). However, there was a significant 
difference in cytotoxicity between the ypN-negative and -posi-
tive groups (53.2±14.1 and 38.7±10.1, respectively; P=0.021). 
Following dichotomization of patients with 45% cut-off value, 
the cytotoxicity assay was the only factor that predicted 
ypN positivity in multivariate analysis (odds ratio, 13; 95% 
confidence interval, 1.2‑133.2; P=0.031). In conclusion, the 
cytotoxicity assay using the 3D cell culture method can be 
used to predict tumor response, particularly ypN positivity, in 
patients with rectal cancer who are scheduled for preop-CRT.
Introduction
Preoperative chemoradiotherapy (preop-CRT) is considered 
as the standard treatment option for locally advanced rectal 
cancer (1). Following reports on the favorable long-term 
oncological outcome of patients with pathologic complete 
response (pCR) (2-4), investigation into potentially useful 
clinicopathological factors for predicting pCR was conducted, 
with various factors proposed to be associated with pCR (5,6). 
Delaying surgery for patients who presented with good clinical 
outcomes has gained popularity recently (7,8). It was reported 
that following preop-CRT in rectal cancer, persistent lymph 
node metastasis (LNM) was the most indicative factor of 
poor prognosis (9,10). In addition, yp node (ypN) positivity 
(metastatic lymph node detection after surgery) was revealed to 
be the most important prognostic factor to predict the survival 
of patients harboring no residual tumor (ypT0) following 
surgical resection (2). There is still some controversy regarding 
this topic, and one of the main concerns with delaying the 
surgery or the local excision approach is the difficulty of 
predicting LNM even in the case of good clinical response. 
Swellengrebel et al (11) reported that 28.5% of patients with no 
residual tumor in the rectal wall had persistent regional LNM 
and 41% of near-complete response patients had ypT3 stage. 
Although several researchers have investigated predictors 
of ypN-positive status following preop-CRT, the studies are 
limited, as the factors used in the nomograms are often diffi-
cult to obtain prior to radical resections (12-14). Considering 
the low predictive rate of the current imaging techniques for 
restaging LNM (15,16), novel strategies to predict LNM more 
accurately following preop-CRT are still warranted.
The 3D cell culture system has been widely used, as cells 
in 3D environments may be more similar to cells in living 
organisms (in vivo) compared to the flat, unnaturally thin and 
single-layer cells grown in 2D environments (17). Typical cells 
in 3D systems are ellipsoids with dimensions of 10-30 µm; 
in contrast, cells in 2D are flat with a typical thickness of 
3 µm (18). With regards to environmental comparison, typical 
cells in 3D have ~100% of their surface area exposed to 
other cells or matrix, whereas cells in 2D have ~50% of their 
surface area exposed to fluid, ~50% exposed to the flat culture 
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surface or intermediate, and very little surface area exposed 
to other cells. A previous data analysis of spheroid-based 
drug screening systems revealed that tumor spheroid size 
and morphology in a 3D culture system was associated with 
in vivo drug sensitivity (19). Previous studies demonstrated 
significantly increased resistance to radiation in tumor cells in 
3D cell culture, in comparison with that of 2D culture (20,21). 
Storch et al (21) reported increased levels of heterochromatin 
in 3D cell cultures that led to increased survival, and a 
decreased number of DNA double‑strand breaks and lethal 
chromosome aberrations in response to radiation, compared 
with those in monolayer cell cultures. These data suggest 
potential clinical benefits of 3D cell culture for predicting 
tumor responses to radiation. Nevertheless, the predictive 
potential of 3D cell culture and cytotoxicity analysis has not 
been widely assessed in patients with rectal cancer who have 
undergone preop-CRT.
Thus, the aim of the present study was to evaluate the 
clinical potential of the 3D cell culture method for predicting 
tumor response to preoperative chemoradiotherapy in patients 
with rectal cancer.
Materials and methods
Patient enrolment. A total of 49 individuals (29 males, aged 
22-82 years) suffering from locally advanced rectal cancer 
that underwent preop-CRT were prospectively enrolled 
at the Severance Hospital, Yonsei University College of 
Medicine (Seoul, Republic of Korea) between August 2015 
and March 2017. Patients with histopathologically confirmed 
adenocarcinoma of the rectum at clinical stage II or III were 
enrolled for the present study (22). All enrolled patients 
underwent preoperative biopsy, for the cytotoxicity assay, 
prior to the initiation of preop-CRT. The protocol used for 
the preop-CRT was described in previous studies (23,24). 
Briefly, the preoperative radiation therapy consisted of a 
total dose of 45 Gy in 25 fractions delivered to the pelvis, 
followed by a 5.4 Gy boost to the primary tumor, over a 
period of 5 weeks (1.8 Gy for 5 days). The pelvic radiation 
volume was as follows: The superior border 1.5 cm above 
the sacral promontory (L5 level); the inferior border at the 
inferior margin of the obturator foramen or 3 cm below 
the lower tumor margin; the lateral border 1.5 cm lateral 
to the bony pelvis; the anterior border 3 cm anterior to the 
tumor; and the posterior border 0.5 cm posterior to the 
sacral surface. The prescription dose was specified at the 
isocenter; the three‑field treatment plan comprised a 6‑MV 
photon posterior-anterior field and 6- or 10-MV photon 
opposed lateral fields with wedges of 45 .˚ For the boost 
treatment, five ports were used. Intravenous bolus injections 
of 5‑fluorouracil/leucovorin (425/20 mg/m2 once per day 
during weeks 1 and 5) or capecitabine (825 mg/m2, twice 
daily during the radiation therapy period) were administered 
to the patients during preop-CRT. Total mesorectal excision 
(TME) was performed 6‑12 weeks after the completion of 
preop-CRT. The protocol of the present study was approved 
by the institutional review board of the Severance Hospital, 
Yonsei University College of Medicine (Seoul, Republic 
of Korea) (approval no. 4-2011-0445). Written informed 
consent was obtained from all participants.
3D cell culture
Tissue harvest. Tissue was collected prior the initiation of 
preop-CRT using rigid sigmoidoscopy and forceps biopsy. 
The tissues were placed into 25-cm2 flasks, filled with RPMI 
culture medium supplemented with 1% penicillin-strepto-
mycin HyClone; GE Healthcare Life Sciences). Before tissue 
dissociation, harvested tissues were maintained at 37˚C in a 
5% CO2 incubator.
Cancer tissue dissociation and 2D culture. Following the 
removal of media from the 25-cm2 flasks, the tissue samples 
were transferred to 1.5-ml micro tubes, and the weight was 
measured. The samples were subsequently transferred to 
60-mm2 dishes filled with 5 ml RPMI culture medium 
supplemented with 1% penicillin-streptomycin and washed by 
pipetting; this procedure was repeated twice. The tissue was 
then transferred to 60-mm2 dishes filled with 5 ml trypsin 
EDTA (HyClone; GE Healthcare Life Sciences), cut into 
smaller pieces using a blade (Nopa Instruments), and incubated 
for 20 min at 37˚C in a 5% CO2 incubator. Subsequently, the 
tissue was harvested using 5 ml RPMI medium supplemented 
with 1% penicillin-streptomycin and 10% FBS (HyClone; GE 
Healthcare Life Sciences), transferred to 15-ml conical tubes, 
and the solution was centrifuged at 260 g for 2 min at room 
temperature. The supernatant was removed, and the pellets 
were resuspended in 10 ml RPMI supplemented with 1% 
penicillin-streptomycin and 10% FBS, followed by transfer-
ring the tissues to 100-mm2 2D culture dishes (Thermo Fisher 
Scientific, Inc.) and incubating at 37˚C for 2‑3 days.
Cancer cell 3D culture. Cells were harvested by pipetting 
and transferred to 15-ml conical tubes. The tissue was then 
transferred to 60-mm2 dishes filled with 5 ml trypsin EDTA 
(HyClone; GE Healthcare Life Sciences), cut into smaller 
pieces using a blade (Nopa Instruments Medizintechnik 
GmbH), and incubated for 20 min at 37˚C in a 5% CO2 incu-
bator. Subsequently, the tissue was harvested using 5 ml RPMI 
medium supplemented with 1% penicillin-streptomycin and 
10% FBS (HyClone; GE Healthcare Life Sciences), transferred 
to 15-ml conical tubes, and the solution was centrifuged at 260 g 
for 2 min at room temperature. The 2D-cultured cells were 
detached using Accumax (EMD Millipore). The dissociated 
cells were counted using a C-Chip disposable hemocytometer 
(INCYTO). The cells were diluted in 1 ml RPMI medium 
supplemented with 1% penicillin-streptomycin and 10% FBS to 
a concentration of 5,000 cells/100 µl and seeded onto ultra-low 
attachment 96-well 3D-culture plates (Corning Inc.).
Radiation treatment. Defining the day on which the cells were 
reseeded for 3D culture as day 0, the 3D-cultured cells were 
treated with 5 Gy radiation at day 3 (Gammacell low dose-rate 
irradiator; Nordion, Inc.). The control group did not receive any 
radiation. The cultured cells were incubated at 37˚C for 2 days.
Imaging before and after radiation treatment. Images of 
3D-cultured cells before and 2 days after radiation treatment 
were acquired by Cell Scanner (MBD), equipped with a x4 
objective lens. The cells and culture media were transferred to 
1.5-ml tubes, and centrifuged at 95 g for 2 min. The supernatant 
and pellets in each tube were stored at ‑20˚C.
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Evaluation of 3D cell culture
Morphological classification. Morphological assessment 
and classification were performed prior to radiation treat-
ment. The resulting spheroids were classified into four 
distinct groups based on morphology as ‘round’, ‘mass’, 
‘aggregate’ and ‘none’ (Fig. 1) (19). For further analysis, 
the ‘round’, ‘mass’, and ‘aggregate’ types were grouped into 
the category ‘mass-forming group’ for efficient statistical 
analysis. The morphological classification was completed by 
an independent researcher, who was unaware of the patients' 
clinicopathological outcomes.
Cytotoxicity analysis. Defining the day on which the cells 
were reseeded for 3D culture as day 0, the culture medium was 
harvested and lactate dehydrogenase (LDH) enzyme activity 
was determined to check cytotoxicity levels at day 5 (2 days of 
additional incubation following radiation treatment). The cells 
were separated from the harvested media by centrifugation at 
1,000 g for 15 min at room temperature. The supernatant was 
collected and the LDH enzyme activity was measured using 
an LDH‑cytotoxicity assay kit (BioVision, Inc.) following the 
manufacturer's protocol. In order to calculate the ratio between 
LDH enzyme activity in the media and cells, the total cellular 
LDH enzyme activity from the cells was also measured.
Measurements of endoscopy and magnetic resonance imaging 
(MRI) parameters. All patients underwent endoscopies from 
4‑6 weeks following completion of preop‑CRT. All endoscopic 
regression grading was estimated by endoscopists. Endoscopic 
grading was classified into endoscopy_CR (normal mucosa, 
whitish scar only), endoscopy_near CR (<1 cm ulcer without 
remaining visible tumor), and endoscopy_non CR (ulcer >1 cm 
without remaining visible tumor, remaining mass regardless 
of ulcer).
Patients underwent two stages of MRI examinations. 
The first examination was performed before the initiation 
of preop-CRT (pre-CRT MRI) and the MRI second was 
performed from 4‑6 weeks following the completion of 
preop-CRT (post-CRT MRI). A 3.0 T scanner [(Magnetom 
Tim Trio; Siemens Medical Solutions) or (Ingenia; Philips 
Medical Systems)] was used for pre- and post-CRT MRI 
examinations. In the present study, magnetic resonance (MR) 
tumor regression grade (TRG), diffusion-weighted image 
(DWI) and MR tumor volume reduction rate (TVRR) were 
evaluated and recorded for each enrolled patient. These 
MRI-based parameters were evaluated based on protocols 
from previous studies (23,25,26).
Tumor response assessment following preop‑CRT. The 
Mandard's classifications were used to evaluate TRG (27). 
pCR was defined as no viable tumor cells in the rectal wall 
along with no LNM. According to the TRG classification, 
TRG 1 and TRG 2 were classified as ‘good tumor response’, 
while TRG 3‑5 were classified as ‘poor tumor response’. 
With respect to tumor downstaging, T downstaging was 
defined as smaller pathologic ypT compared with clinical 
T stage, and N downstaging was defined as conversion of 
clinically positive lymph nodes to pathologically negative 
status. 
Statistical analysis. All statistical analyses were performed 
using SPSS version 23.0 (IBM Corp.). Categorical variables 
were analyzed using the χ2 test or Fisher's exact test, and 
continuous variables were analyzed using Student's t-test or 
ANOVA. Receiver operating characteristic (ROC) curve 
analysis was used to compare the diagnostic performance 
of the parameter for predicting ypN positivity. The cut-off 
values for the variables that provided the best classification 
between the groups were determined. Factors associated with 
ypN positivity were analyzed by logistic regression analysis 
with forward stepwise selection of variables. All variables 
with P<0.2 on univariate analysis were initially entered into 
the multivariate analysis. P<0.05 was considered statistically 
significant.
Figure 1. Four types of morphology of 3D spheroids formed in 3D cell cultures. The 3D spheroids formed by 3D cell culture of rectal cancer tissues, obtained 
before preoperative chemoradiotherapy, were grouped as (A) ‘round’, (B) ‘mass’, (C) ‘aggregate’ and (D) ‘none’ types.
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Results
A total of 49 patients were initially enrolled in the present 
study for performing a cytotoxicity assay on 3D-cultured cells 
exposed to radiation. Finally, the results from 26 patients (53%) 
were available for further analysis. The reasons for failure in 
obtaining results from the remaining patients comprised cell 
culture contamination for 15 (65%) patients and insufficient 
specimens from the biopsy for 8 (35%) patients. There was 
no difference in clinicopathological characteristics between 
the success group (n=26) and the failure group (n=23; 
Table I). Among the 26 patients included in the final analysis, 
cytotoxicity ranged from 25.5-72.6% (median, 47.6%).
By morphologic classifications, the ‘aggregate’ type was 
the most common (57.7%), followed by the ‘none’ type (26.9%). 
Mean and the standard deviation of cytotoxicity were 50.9 in 
‘round’ type, 51.2±10.7 in mass type, 52.4±16.8 in aggregate 
type and 41.9±9.3 in none type respectively. With respect to 
Table I. Comparison of clinicopathological factors according to the success or failure of patients that were included in the 
cytotoxicity assay.
Clinicopathological factor Success group (n=26), n (%) Failure group (n=23), n (%) P-value
Sex   0.562
  Male 14 (53.8) 15 (65.2) 
  Female 12 (46.2) 8 (34.8) 
Age, years   0.332
  <65 21 (80.8) 15 (65.2) 
  ≥65 5 (19.2) 8 (34.8) 
BMI, kg/m2 24.1±3.7a 22.8±2.6a 0.167
Distance from anal verge, cm 6.2±2.1a 5.9±2.3a 0.661
Tumor location   0.394
  Low (<5 cm) 9 (34.6) 11 (47.8) 
  Middle (5-10 cm) 17 (65.4) 12 (52.2) 
CEA (initial), µg/l 6.0±7.4a 6.5±7.5a 0.796
cT stage   0.286c
  cT2 0 2 (8.7) 
  cT3 23 (88.5) 20 (87) 
  cT4 3 (11.5) 1 (4.3) 
cN stage   0.4c
  Node-negative 2 (7.7) 4 (17.4) 
  Node-positive 24 (92.3) 19 (82.6) 
Cytotoxicity, % (range) 47.6b (25.5-72.6) N/A
aMean ± standard deviation. bMedian. cFisher's exact test. BMI, body mass index; CEA, carcinoembryonic antigen; N/A, not available; 
cT, clinical tumor; cN, clinical node.
Table II. Association of cytotoxicity assay with 3D morphologic classification before radiation.
Parameters n=26, n (%) Cytotoxicity, mean ± SD P-value
3D morphologic classificationa   0.490c
  Round 1 (3.8) 50.9 
  Mass 3 (11.5) 51.2±10.7 
  Aggregate 15 (57.7) 52.4±16.8 
  None 7 (26.9) 41.9±9.3 
Subgroup analysis   0.113
  ‘Mass-forming group’b 19 (73) 52.1±15.3 
  ‘None group’ 7 (26.9) 41.9±9.3 
a3D morphologic classification was analyzed before radiation treatment. bMorphologic classification of ‘round’, ‘mass’ and ‘aggregate’ were 
classified into ‘mass forming’ group and ‘none’ was classified into the ‘none’ group. cAnalyzed by ANOVA test.
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associations between cytotoxicity and 3D morphologic clas-
sification, there were no differences in cytotoxicity among the 
4 groups. Following the grouping of the ‘round’, ‘mass’ and 
‘aggregate’ types into the ‘mass-forming’ group, there were 
no differences in the cytotoxicity between the ‘mass-forming 
group’ and the ‘none group’ (Table II).
With respect to the association between cytotoxicity and 
pathologic tumor response (Table III), there was no differ-
ence in cytotoxicity based on either the TRGs 1-5, (P=0.940) 
or good tumor response (TRGs 1-2 vs. TRGs 3-5; P=0.729). 
There was a weak association between cytotoxicity and N 
downstaging status (52.8±14.3 in the N downstaging-positive 
group vs. 42.8±13.2 in the N downstaging-negative group; 
P=0.096). In contrast, there was a significant difference in 
cytotoxicity between the ypN-positive and the ypN-negative 
groups (53.2±14.1 vs. 38.7±10.1, respectively; P=0.021).
The morphological classifications were associated with 
pathologic tumor response. The rate of T downstaging was 
marginally higher in the ‘mass-forming group’ compared 
to that of the ‘none group’ (73.7% vs. 28.6%, respectively; 
P=0.069). Although the ypN-positive rate was lower in the 
‘mass-forming group’ (15.8%) compared with that in the ‘none 
group’ (57.1%), the difference was not statistically significant 
(P=0.057; Table IV). The ROC curves were generated for cyto-
toxicity in patients with ypN-positive status and the area under 
the curve was 0.801. Using the ROC curves, the Youden's 
index was calculated to be 45.05 (Fig. 2). 
Using the Youden's index value as the cut-off value, 
the patients were dichotomized into low-cytotoxicity and 
high-cytotoxicity groups. There were no differences in the 
clinicopathological and radiological parameters between the 
high- and low-cytotoxicity groups, except for the ypN-positivity 
(Table V). The high‑cytotoxicity group showed significantly 
lower ypN-positivity (7.1%) than that of the low-cytotoxicity 
group (50%; P=0.026).
3D morphologic classification and cytotoxicity assay data 
were considered in the final multivariate analysis to predict the 
ypN-positivity (Table VI). The cytotoxicity (dichotomized as 
low vs. high) was the only factor that predicted ypN-positivity 
in the multivariate analysis (high-cytotoxicity vs. low-cyto-
toxicity; odds ratio, 13; 95% confidence interval, 1.2‑133.2; 
P=0.031).
Discussion
The present study demonstrated that the cytotoxicity assay, 
using 3D cell culture with radiation, could be a novel alterna-
tive for predicting lymph node positivity following preop-CRT 
in rectal cancer.
Increasing evidence has suggested that good tumor 
response following preop-CRT may warrant a decrease in 
radical resection and promotion of an approach that involves 
either delaying the surgery or local excision (28,29). However, 
the basic prerequisite for these approaches is no or minimal 
possibility of regional LNM. Accurate preoperative assess-
ment of LNM is crucial for effectively employing the delay in 
surgery or radical resection approaches in patients suspected 
of clinical complete response. Nevertheless, it was reported 
that current imaging tools have low sensitivity or specificity 
for defining LNM following preop‑CRT (15). The reliability 
of imaging techniques for evaluating lymph node positivity 
following preop‑CRT in rectal cancer is known to be poor, 
and there are no standard guidelines to define lymph node 
positivity (30).
In order to overcome these inherent limitations of 
imaging-based detection of lymph node positivity following 
preop-CRT, a clinical outcome-based prediction model was 
introduced. Jwa et al (12) reported that patient age, ypT 
stage, tumor differentiation, clinical N stage, lymphovascular 
invasion (LVI) and perineural invasion (PNI) could reliably 
predict LNM following preop-CRT. A nomogram using these 
parameters was developed and showed high similarity between 
nomogram-predicted and real lymph node positivity following 
preop-CRT. Although the nomogram was based on a relatively 
large and homogeneously treated patient group from a single 
center, this nomogram included pathological parameters such 
as ypT stage, LVI and PNI that can be more accurately derived 
from resected rectum, following definite TME, compared to 
preoperative biopsy specimens. The use of this nomogram 
Table III. Association of cytotoxicity with pathologic tumor 
response.
  Cytotoxicity, 
Parameters N mean ± SD P-value
TRG grade   0.940a
  1 6 50±18.6 
  2 4 45.2±8.9 
  3 11 50.8±12.8 
  4 5 48.8±19.8 
  5 0  
TRG response   0.729
  TRG 1-2 10 48.1±15 
  TRG 3-5 16 50.1±14.6 
pCR   0.909
  Yes 6 50±18.6 
  No 20 49.2±3.6 
T downstaging   0.199
  Positive 16 52.3±14 
  Negative 10 44.6±14.7 
N downstaging   0.096
  Positive 17 52.8±14.3 
  Negative 9 42.8±13.2 
yp T stage   0.895a
  0 6 50±18.6 
  1 1 53.8 
  2 8 51.8±11.5 
  3 11 46.8±15.7 
yp N stage   0.021
  Node-negative 19 53.2±14.1 
  Node-positive 7 38.7±10.1 
aAnalyzed by ANOVA test. TRG, tumor regression grade; pCR, 
pathologic complete response; T, tumor; N, node.
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may therefore be limited in deciding on proceeding for radical 
surgery.
In the present study, a cytotoxicity assay was conducted 
to predict tumor response following preop-CRT. However, 
the assay could not predict postoperative pCR or good tumor 
response (TRGs 1-2). In contrast, low cytotoxicity, dichoto-
mized by a 45% cut-off in the cytotoxicity assay, was associated 
with ypN positivity. Notably, most of the well‑known possible 
predictors of pCR, such as endoscopy grade, MR TRG, MR 
TVRR and MR DWI demonstrated no associations with 
ypN positivity, which confirms the difficulties in predicting 
lymph node status using clinical variables. Nevertheless, the 
underlying mechanism of the association between ypN posi-
tivity and the cytotoxicity assay cannot be elucidated from the 
findings of the present study. It may be associated with the 
difference between the radiation responses of primary tumors 
and metastatic lymph nodes, considering the lack of association 
between the cytotoxicity level and TRG. The current practice of 
local excision following good clinical response indicated that 
metastatic lymph nodes may regress at the same level as the 
primary tumor following preop-CRT, which was supported by 
the clinical observations (31,32). In contrast, a study reported 
28.5% lymph node positivity in patients who exhibited pCR 
(ypT0) (11). Moreover, Choi et al (33) demonstrated that lymph 
Figure 2. Receiver-operating characteristic curve of 3D cell culture cyto-
toxicity following radiation and yp node positivity following surgery. The 
AUC was 0.801 (95% CI, 0.599-0.930). The optimal cut-off point was calcu-
lated as 45.05%, according to Youden's index. AUC, area under the curve; 
CI, confidence interval.
Table IV. Association of 3D morphologic classification with pathologic tumor response.
Parameters N Mass-forming group (n=19), n (%) None group (n=7), n (%) P-value
TRG grade    0.292a
  1 6 6 (31.6) 0 
  2 4 2 (10.5) 2 (28.6) 
  3 11 7 (36.8) 4 (57.1) 
  4 5 4 (21.1) 1 (14.3) 
  5 0 0 0 
TRG response    0.668a
  TRG 1-2 10 8 (42.1) 2 (28.6) 
  TRG 3-5 16 11 (57.9) 5 (71.4) 
pCR    0.146a
  Yes 6 6 (31.6) 0 
  No 20 13 (68.4) 7 (100) 
T downstaging    0.069a
  Positive 16 14 (73.7) 2 (28.6) 
  Negative 10 5 (26.3) 5 (71.4) 
N downstaging    0.188
  Positive 17 14 (73.7) 3 (42.9) 
  Negative 9 5 (26.3) 4 (57.1) 
yp T stage    0.252a
  0 6 6 (31.6) 0 
  1 1 1 (5.3) 0 
  2 8 6 (31.6) 2 (28.6) 
  3 11 6 (31.6) 5 (71.4) 
yp N stage    0.057a
  Node-negative 19 16 (84.2) 3 (42.9) 
  Node-positive 7 3 (15.8) 4 (57.1) 
aFisher's exact test. TRG, tumor regression grade; pCR, pathologic complete response; T, tumor; N, node.
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node regression grade (LRG) following preop-CRT was the 
only independent factor associated with relapse-free survival 
in patients with ypN-positive rectal cancer, who underwent 
preop‑CRT. One of the interesting findings of this study was 
that the distribution of LRG was not associated with the TRG 
of the primary tumor, and that the LRG of each metastatic 
lymph node differed from the other within the same patient. 
These findings meant that the effects of radiation could differ 
between the primary tumor and metastatic lymph nodes. 
These discrepancies may be a possible reason for the different 
prediction powers of primary tumor cells and lymph node 
positivity in the cytotoxicity assays described in the present 
study. However, there was no ypN positivity in patients with 
ypT0; thus, considering the relatively low rate of ypN-positive 
results in patients with ypT0 in a previous study (2), further 
large-scale investigation may be required to elucidate the true 
mechanisms underlying the observations of the present study.
The cytotoxicity assay, following 3D cell culture and radia-
tion, had certain advantages. Firstly, the 7-day turnaround time 
for this procedure was acceptable, as long turnaround times 
could hinder clinical decision‑making. Secondly, the assay can 
predict patients' tumor response before initiating preop-CRT. 
Although preop-CRT decreased the local recurrence rate more 
than postoperative adjuvant CRT, overall survival gain was 
not anticipated. Rather, preop-CRT may be associated with 
delayed adverse effects on long-term anorectal, sexual and 
Table V. Clinicopathological characteristics and magnetic resonance parameters according to the low- and high-cytotoxicity 
groups.
 Low-cytotoxicity group  High-cytotoxicity group 
 (≤45; n=12), n (%) (>45; n=14), n (%) P‑value
Sex   >0.999
  Male 6 (50) 8 (57.1) 
  Female 6 (50) 6 (42.9) 
Age, years 51.4±10.8a 54.9±16.2a 0.530
BMI, kg/m2 23.7±3.5a 24.5±4a 0.575
Distance from anal verge, cm 6.1±2.1a 6.2±2.2a 0.875
CEA (initial), µg/l 6.5±7a 5.6±8a 0.759
yp T stage   0.933a
  T0 3 (25) 3 (21.4) 
  T1 0 1 (7.1) 
  T2 3 (25) 5 (35.7) 
  T3 6 (50) 5 (35.7) 
yp N stage   0.026b
  Node-negative 6 (50) 13 (92.9) 
  Node-positive 6 (50) 1 (7.1) 
pCR   >0.999b
  Yes 3 (25) 3 (21.4) 
  No 9 (75) 11 (78.6) 
Endoscopy   0.190b
  Endoscopy_non CR 7 (58.3) 12 (85.7) 
  Endoscopy_CR and endoscopy_near CR 5 (41.7) 2 (14.3) 
MR TRG   0.683b
  Grade I and II 7 (58.3) 10 (71.4) 
  Grade III-V 5 (41.7) 4 (28.6) 
MR Tumor volume, cm3   
  Pre-CRT 17.2±10.0a 25.6±14.1a 0.098
  Post-CRT 6.9±5.4a 8.6±6.0a 0.467
TVRR, % 62.4±20.9a 66.1±14.3a 0.603
MR DWI   1.0b
  Negative 4 (33.3) 4 (28.6) 
  Equivocal and positive 8 (66.7) 10 (71.4) 
aMean ± standard deviation. bFisher's exact test. CEA, carcinoembryonic antigen; BMI, body mass index; T, tumor; N, node; pCR, patho-
logic complete response; CR, complete response; MR, magnetic resonance; TVRR, tumor volume reduction rate; CRT, chemoradiotherapy; 
TRG, tumor regression grade; DWI, diffusion weighted image; SD, standard deviation.
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urinary dysfunction (34). In this regard, a study demonstrated 
the efficacy of initiating chemotherapy in conjugation with 
selective radiation treatments (35). One reason for employing 
this new approach is the speculation that radiation-induced 
complications may be decreased. Several tumor response 
assays currently used in practice were considered as response 
evaluation tools rather than prediction models. MRI-based 
tumor volumetric evaluation, DWI, MR TRG, endoscopy 
grading, delay of surgery and other variables can be evaluated 
post-preop-CRT; however, these cannot predict tumor response 
before initiating preop-CRT. In this regard, the cytotoxicity 
assay may be useful for predicting whether a patient should 
undergo preop-CRT, although the actual clinical benefits 
should be evaluated with further investigations.
Nevertheless, there were several potential limitations of 
the present study. Immediate storage of fresh tissue in 25-cm2 
flasks, filled with RPMI culture medium supplemented with 1% 
penicillin-streptomycin is mandatory for the analysis. Although 
board‑certified surgeons performed the pre‑treatment biopsies, 
it is not always possible to obtain adequate tissue using rigid 
sigmoidoscopy. Another limitation was cell contamination 
during the cell culture process. It is well known that the intestinal 
and feces flora is mostly composed of obligate anaerobes such 
as Bacteroides and Bifidobacterium, and the accompanying 
bacteria during the biopsy process may contaminate the culture. 
The failure rate, due to cell contamination, cannot be ignored in 
the present study, which may hinder this procedure and therefore, 
a modified protocol is required to overcome this issue.
Table VI. Univariate and multivariate analysis of factors associated with yp node positivity.
 Univariate analysis Multivariate analysis
 ---------------------------------------------------------------------- ----------------------------------------------------------
Parameters N N (%) P-value OR (95% CI) P-value
Sex   >0.999a  
  Male 14 4 (28.6)   
  Female 12 3 (25)   
Age, years   0.278a  
  <65 21 7 (33.3)   
  ≥65 5 0   
cT   >0.999a  
  T3 23 6 (26.1)   
  T4 3 1 (33.3)   
cN   >0.999a  
  Node negative 2 0   
  Node positive 24 7 (29.2)   
Endoscopy grade   0.629a  
  Endoscopy_non‑CR 19 6 (31.6)   
  Endoscopy_CR and endoscopy_near CR 7 1 (14.3)   
MR TRG   0.661a  
  Grade I and II 9 3 (33.3)   
  Grade III-V 17 4 (23.5)   
MR TVRR (%)   0.540a  
  <83.6 23 7 (30.4)   
  ≥83.6 3 0    
MR DWI   0.375a  
  Negative 8 1 (12.5)   
  Equivocal and positive 18  6 (33.3)   
3D morphologic classification   0.057a  
  ‘Mass-forming group’ 19 3 (15.8)   
  ‘None group’ 7 4 (57.1)   
Cytotoxicity assay   0.026a  0.031
  High (>45) 14 1 (7.1)  1 
  Low (≤45) 12 6 (50)  13 (1.2‑133.2) 
aFisher's exact test. CR, complete response; pCR, pathologic complete response; TRG, tumor regression grade; TVRR, tumor volume reduction 
rate; DWI, diffusion weighted image; MR, magnetic resonance; T, tumor; N, node.
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The main limitation of the present study was its small 
sample size. In a previous study concerned with perme-
ability, based on the spheroid ‘round’-type morphological 
characteristic, increased resistance to drug therapy was 
observed compared with ‘aggregate’, ‘mass’ or ‘none’ 
types, which was associated with the Janus kinase‑STAT 
signaling pathway (19). However, in the present study, the 
‘mass’, ‘aggregate’ and ‘round’ types were grouped into 
the ‘mass-forming’ group, as the mean cytotoxicity level 
following radiation was similar among the ‘round’, ‘mass’ 
and ‘aggregate’ types. Although the response of the 3D 
spheroids to radiation treatment may be entirely different 
from the response to chemotherapy, the limited number of 
enrolled patients may hinder the detailed comparison. There 
are potential differences according to the definitions of ypT 
stage and TRG. Even with the same ypT3, some patients had 
small islets of viable cancer cells scattered in the subserosa 
layer that showed predominant fibrosis (good TRG), whereas 
other patients have ypT3 tumors in which most cancer cells 
remain viable (poor TRG) (36). Due to the small sample size 
in the present study, whether the differences in TRG of the 
same ypT stage were associated with the cytotoxicity assay 
could not be analyzed. Finally, it was also possible that the 
cytotoxicity assay may not accurately reflect humans' resis-
tance to radiation and it does not accurately reproduce the 
surrounding environments of patients with rectal cancer. 
This needs to be validated in further studies.
In conclusion, a cytotoxicity assay following 3D cell 
culture and radiation predicted ypN positivity in patients with 
locally advanced rectal cancer that underwent preop-CRT. 
The preliminary findings of the present study may be useful 
in conducting further studies on this matter, which can poten-
tially lead to clinical application in decision‑making prior to 
initiating preoperative chemoradiotherapy.
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